Bank7 Corp. (BSVN)
Valuation Overview•Is Bank7 Corp. Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
High-quality fundamentals with a strong composite quality score of 79/100, backed by robust profitability and solvency.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Solid fundamental quality, though solvency presents a headwind.
Wall Street sentiment is generally neutral. This is paired with healthy capital returns, anchored by a strong, well-covered dividend yield.
BSVN exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins. This is backed by a fortress balance sheet, holding significant net cash ($245M) and minimal debt risk.
The company demonstrates solid revenue growth (10.0% 3Y CAGR) paired with robust earnings compounding (11.8% EPS 3Y CAGR). This growth is supported by elite operational efficiency, sustaining an impressive 42.5% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $26.2M | -1.1% | +10.0% | +14.6% | — | |
| EBITDA | $17.0M | — | +12.5% | — | — | |
| Net Income | $12.0M | -5.8% | +13.3% | — | — | |
| EPS (Diluted) | $1.25 | -7.0% | +11.8% | +17.0% | — | |
| Free Cash Flow | $14.2M | -18.6% | +1.6% | +10.8% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 70.5% | 64.2% | 72.6% | 78.2% |
| Operating Margin | 42.5% | 37.4% | 42.6% | 44.4% |
| Net Margin | 31.8% | 28.3% | 32.2% | 36.5% |
| FCF Margin | 30.0% | 33.7% | 40.0% | 42.9% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q3'26Latest | $1.03 | $0.87 | -15.5% | ||
| Q2'26 | $1.01 | $1.25 | +23.8% | ||
| Q1'26 | — | $1.12 | — | ||
| Q1'26 | $1.05 | $1.12 | +6.7% | ||
| Q1'26 | $1.03 | $1.12 | +8.7% | ||
| Q4'25 | $1.03 | $1.13 | +9.7% | ||
| Q3'25 | $0.98 | $1.16 | +18.4% | ||
| Q2'25 | $0.97 | $1.08 | +11.3% |
Total return is +17.7% (1Y), outperforming the benchmark by +1.9%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +35.2% | +22.8% | — |
| 1Y | +17.7% | +1.9% | +2.3% |
| 3YCAGR | +35.8% | +13.5% | +13.7% |
| 5YCAGR | +23.6% | +11.8% | +20.2% |
| 10YCAGR | +12.2% | -1.4% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Bank7 Corp. (BSVN) valuation, health, and returns.
Based on peer relative multiples, Bank7 Corp. appears Fair versus peers compared to industry peers.
Bank7 Corp. has multiple valuation anchors: Peer Relative Fair Value: $56.64 | Wall Street Analyst Target: $57.00 (implying +3.4% upside). A convergence of these signals offers higher conviction.
Bank7 Corp. displays good financial health with a composite quality score of 79/100, supported by a Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 18.3%.
Bank7 Corp. pays a 1.8% dividend yield, covered by a 22% payout ratio with 7 years of growth, supplemented by a 0.2% buyback yield.
Bank7 Corp.'s current growth trajectory is Decelerating. The company achieved -1.1% 1Y revenue growth and -7.0% 1Y EPS growth, compared to its 3Y revenue CAGR of +10.0%.
Wall Street consensus is Buy based on 3 analysts, beating EPS expectations in 83% of recent quarters with a -1-quarter streak. The consensus price target represents a +3.4% change from current levels.
Investment risks for Bank7 Corp. include: -21.7% 1-year max drawdown. Volatility risk is characterized by a beta of 0.31x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.